Expert Interviews

Panelists discuss how dual NK3/NK1 receptor antagonism may expand therapeutic benefits by targeting multiple neural pathways involved in VMS and mood regulation.

Panelists discuss how NK3 receptor antagonism through fezolinetant offers effective, rapid relief from VMS with a strong safety profile and nonhormonal benefits.

TMS: Harvard's Caroline Mitchell, MD, MPH, questions the direction of genitourinary syndrome research priorities and reflects on FDA's removal of HRT warnings.

Women increasingly seek evidence-based menopause care as awareness grows, yet many still suffer from untreated vasomotor symptoms.

Harvard's Caroline Mitchell, MD, MPH, explains how common OTC products can worsen vulvovaginal symptoms and the importance of a targeted history in GSM care.

Access, cost, and clinician awareness remain significant barriers to implementing supplemental breast screening, according to Plecha.

Breast imaging expert Donna M. Plecha, MD, explains the FDA's dense breast notification requirement and when to recommend supplemental MRI screening.

Mitchell highlights hormone therapy prescribing for primary care: treatment algorithms, vaginal estrogen safety, and when progestins aren't needed.

Panelists discuss how NK receptor antagonism provides a targeted, nonhormonal strategy that addresses the physiological root of vasomotor symptoms.

Panelists discuss how limited treatment options and systemic barriers underscore the urgent need for accessible, targeted therapies for vasomotor symptoms.